---
title: "Citizens Maintains Market Outperform on CRISPR Therapeutics (CRSP) Despite Casgevy Slowdown"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/267937711.md"
description: "Citizens reaffirmed its Market Outperform rating and $86 price target for CRISPR Therapeutics AG, citing positive findings from CRISPR's presentation on CTX310 at the American Heart Association, despite a slowdown in Casgevy."
datetime: "2025-11-29T18:23:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/267937711.md)
  - [en](https://longbridge.com/en/news/267937711.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/267937711.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/267937711.md) | [繁體中文](https://longbridge.com/zh-HK/news/267937711.md)


# Citizens Maintains Market Outperform on CRISPR Therapeutics (CRSP) Despite Casgevy Slowdown

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best short squeeze stocks to buy right now. Citizens reaffirmed its Market Outperform rating and $86 price target for CRISPR Therapeutics AG (NASDAQ:CRSP) on November 11. The firm discussed positive findings from CRISPR’s American Heart Association presentation on CTX310, targeted at ANGPTL3 for a variety of cholesterol issues. \[…\]

### Related Stocks

- [CRISPR Therapeutics AG (CRSP.US)](https://longbridge.com/en/quote/CRSP.US.md)

## Related News & Research

- [USPTO Ruling Impacts Editas Medicine CRISPR IP Position](https://longbridge.com/en/news/280795333.md)
- [Why CRISPR Therapeutics (CRSP) Is Up 6.1% After Positive CTX310 Trial and Earnings Beat](https://longbridge.com/en/news/267887939.md)
- [GE Healthcare Technologies Takes Lead Industrial Role in Cardio-Oncology Initiative in Europe](https://longbridge.com/en/news/280636292.md)
- [Banner|Aetna Brings Community Together for 2026 Phoenix Heart Walk](https://longbridge.com/en/news/280833134.md)
- [Lexeo Therapeutics Advances Cardiac Gene Therapies, Strengthens Finances](https://longbridge.com/en/news/281090118.md)